Vivoryon Therapeutics N.V. (VVY.AS)

EUR 1.97

(0.71%)

Annual Income Statements

(In EUR)
Breakdown 2023 2022 2021 2020 2019 2018
Revenue -3.62 Million - 10.76 Million - - -
Cost of Revenue -525 Thousand 161 Thousand 1.73 Million 146 Thousand 88 Thousand 23 Thousand
Gross Profit -3.09 Million -161 Thousand 9.03 Million -146 Thousand -88 Thousand -23 Thousand
Operating Expenses 24.69 Million 28.97 Million 21.83 Million 15.87 Million 7.68 Million 7.7 Million
Selling, General and Administrative Expenses 3.27 Million 8.74 Million 4.38 Million 2.66 Million 2.93 Million 2.86 Million
Research and Development Expenses 17.63 Million 20.22 Million 17.45 Million 13.21 Million 4.75 Million 4.83 Million
Other Expenses 4.83 Million - - - - -
Cost and Expenses 25.21 Million 29.13 Million 23.57 Million 16.01 Million 7.77 Million 7.72 Million
Operating Income -28.83 Million -29.13 Million -12.8 Million -16.01 Million -7.77 Million -7.72 Million
Interest Expense 56 Thousand 24 Thousand 24 Thousand 23 Thousand 108 Thousand -
Income Tax Expense -234 Thousand -199 Thousand 432 Thousand - - -138.14 Thousand
Earnings before Tax -28.57 Million -28.35 Million -12.22 Million -16.51 Million -7.82 Million -7.73 Million
Net Income -28.34 Million -28.15 Million -12.65 Million -16.51 Million -7.82 Million -7.73 Million
Earnings Per Share Basic -1.12 -1.28 -0.63 -0.83 -0.62 -0.92
Earnings Per Share Diluted -1.12 -1.28 -0.63 -0.83 -0.62 -0.92
Weighted Average Shares Outstanding 25.24 Million 22.01 Million 20 Million 19.97 Million 12.54 Million 8.37 Million
Weighted Average Shares Outstanding (Diluted) 25.24 Million 22.01 Million 20 Million 19.97 Million 12.54 Million 8.37 Million
Gross Margin 0.85 - 0.84 - - -
EBIT Margin 7.83 - -1.17 - - -
Profit Margin 7.83 - -1.18 - - -
EBITDA -28.35 Million -28.17 Million -12.03 Million -16.34 Million -7.62 Million -7.67 Million
Earnings Before Tax Margin 7.97 - -1.19 - - -

Income Statement Charts